MorphoSys AG (NASDAQ:MOR) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET
Company Participants
Julia Neugebauer - Head of Investor Relations
Jean-Paul Kress - Chief Executive Officer
Tim Demuth - Chief Research and Development Officer
Sung Lee - Chief Financial Officer
Joe Horvat - General Manager MorphoSys US
Conference Call Participants
James Quigley - Morgan Stanley
James Gordon - J.P. Morgan
Rajan Sharma - Goldman Sachs
Suzanne van Voorthuizen - Kempen & Co
Mohamad Vaseghi - Frankfurt Main Research
Julia Neugebauer
Ladies and gentlemen, good afternoon and good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys, and it's my pleasure to welcome you to our Fourth Quarter and Full Year 2022 Financial Results Conference Call.
Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Tim Demuth, Chief Research and Development Officer; and Joe Horvat, US General Manager who will join for the Q&A.
Before we begin, I'd like to remind you on slide two that some of our statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans and expectations for the compounds in our pipeline as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys' 20-F and annual report, all for the year ended December 31, 2022, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements in this webcast speak as of today.
On slide three, you'll find the agenda for today's call. Jean-Paul will begin with an overview and will give an outlook. Then Tim will provide an update on our development pipeline, before turning the call to Sung for a summary of our fourth quarter and full year 2022 financial results. Following these prepared remarks, we will open the call for your questions.
With that, I now hand the call over to Jean-Paul.
Jean-Paul Kress
Thank you Julia. Good morning and good afternoon, everyone. Thanks for joining us today. 2022 was another transformative year for MorphoSys. We are determined to have two medicines available to cancer patients by 2025, and we are confident that we will accomplish this. This confidence is reinforced by our clear strategy, highly qualified team, financial strength, and most importantly, the best-in-class mid to late stage pipeline.